ID   SKBR3 A3
AC   CVCL_YX81
DR   cancercelllines; CVCL_YX81
DR   Wikidata; Q98132677
RX   PubMed=20386540;
CC   Population: Caucasian.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:2594; CYP19A1.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P00552; Transposon Tn5 neo.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 12-03-20; Last updated: 19-12-24; Version: 10
//
RX   PubMed=20386540; DOI=10.1038/sj.bjc.6605641; PMCID=PMC2856013;
RA   Evans A.H., Pancholi S., Farmer I., Thornhill A., Evans D.B.,
RA   Johnston S.R.D., Dowsett M., Martin L.-A.;
RT   "EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in
RT   HER2/ER-positive breast cancer cells but functions synergistically
RT   with endocrine therapy.";
RL   Br. J. Cancer 102:1235-1243(2010).
//